Comparative Pharmacology
Head-to-head clinical analysis: ELYXYB versus VIOXX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELYXYB versus VIOXX.
ELYXYB vs VIOXX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical analgesic; inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in peripheral tissues.
Selective cyclooxygenase-2 (COX-2) inhibitor; reduces prostaglandin synthesis involved in inflammation, pain, and fever.
Topical application of 5.6 g (one unit dose tube) to the target area of the forehead and temple using the hand-held applicator, applied only once per migraine attack. Maximum dose: 5.6 g per day.
12.5 to 25 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in healthy adults. No clinically relevant accumulation with repeated dosing at recommended intervals.
The terminal elimination half-life is approximately 17 hours (range 12-22 hours) in healthy adults. This prolonged half-life supports once-daily dosing, but accumulation occurs with repeated doses, reaching steady state within 3-4 days. In elderly patients, half-life may increase by up to 30%.
Primarily renal excretion of metabolites; 70-80% of dose recovered in urine as glucuronide conjugates, with <1% as unchanged drug. Biliary/fecal excretion accounts for approximately 10-20%.
Rofecoxib is primarily eliminated via hepatic metabolism, with <1% excreted unchanged in urine. Approximately 72% of an oral dose is excreted in urine as metabolites and 14% in feces as metabolites. Biliary excretion contributes minimally.
Category C
Category C
NSAID (COX-2 Inhibitor)
NSAID (COX-2 Inhibitor)